TR2-A single dose study; version 1

• Research type

  Research Study

• Full title

  An open study to assess the pharmacokinetics and pharmacodynamics of TR2A,\na putative prodrug of the\ngastrin/CCK2 receptor antagonist, TR2, in healthy subjects (15001)

• IRAS ID

  172158

• Contact email

  rec@hmrlondon.com

• Sponsor organisation

  Trio Medicines Ltd

• Eudract number

  2014-005237-31

• Duration of Study in the UK

  1 years, 0 months, 0 days

• Research summary

  Research summary not currently available.

• REC name

  London - Brent Research Ethics Committee

• REC reference

  15/LO/0115

• Date of REC Opinion

  18 Mar 2015

• REC opinion

  Further Information Favourable Opinion